Prevalence, clinical characteristics, and treatment outcomes of childhood tuberculosis in Nigeria: a systematic review and meta-analysis.

Publication date: Dec 19, 2024

Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a leading cause of infection-related deaths worldwide. Children with underdeveloped immune systems are particularly vulnerable, experiencing symptoms akin to common childhood illnesses. Early diagnosis and treatment typically yield positive outcomes. In Nigeria, childhood TB is underreported, complicating accurate burden assessment. This review synthesises and presents evidence on the disease prevalence among children in Nigeria, identifies clinical characteristics, and evaluates the effectiveness of treatment regimens and outcomes. A comprehensive systematic search across electronic databases was conducted to retrieve studies on the prevalence, characteristics, diagnostic criteria, and treatment outcomes of childhood tuberculosis in Nigeria. Study registration, data extraction and quality assessment followed standardized guidelines. The meta-analysis used a random-effects model to determine prevalence and mean treatment outcomes. Statistical heterogeneity was assessed using the I^2 statistic, and publication bias was evaluated with Egger’s test (p = 0. 127) and a funnel plot. This review and meta-analysis of 22 studies, primarily retrospective (77%) and cross-sectional (18. 20%), involving 1,162,936 participants aged 0-18 years, found a pooled prevalence of 20. 82% (95% CI: 8. 55-36. 64)) with high heterogeneity (I = 99. 88%). Pulmonary tuberculosis is the most common form in children 62. 70% (95%: 43. 57-80. 03) diagnosed using sputum smear microscopy, GeneXpert MTB/RIF assays, chest radiographs, and tuberculin skin tests. Clinical diagnosis based on symptoms, contact history, and radiological findings is crucial for younger children unable to produce sputum, as laboratory tests confirm only 6% of cases. Treatment involves the use of rifampicin, isoniazid, pyrazinamide, and ethambutol per national and international guidelines. The meta-analysis showed an average treatment success rate of 75. 47%%, but challenges such as loss to follow-up (11. 40%)) and increasing mortality rates (6. 76%) persist. The burden of childhood tuberculosis in Nigeria is significant, even as diagnostic limitations pose constraints. The findings highlight the need for stronger health system collaborations to improve the quality of care offered to children diagnosed with TB. Future research should standardize diagnostic criteria and methodologies for consistent and reliable prevalence estimates. More longitudinal studies are necessary to comprehend the trend and pattern for the heightened prevalence and subpar treatment outcomes of childhood tuberculosis in Nigeria. CRD42024586765.

Open Access PDF

Concepts Keywords
Crd42024586765 Adolescent
Laboratory Antitubercular Agents
Pyrazinamide Antitubercular Agents
Tuberculosis Child
Child, Preschool
Childhood tuberculosis
Humans
Infant
Mycobacterium tuberculosis
Nigeria
Nigeria
Prevalence
Prevalence
Treatment Outcome
Treatment outcome
Tuberculosis
Tuberculosis

Semantics

Type Source Name
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH infection
disease IDO quality
disease MESH Pulmonary tuberculosis
disease IDO history
drug DRUGBANK Rifampicin
drug DRUGBANK Isoniazid
drug DRUGBANK Pyrazinamide
drug DRUGBANK Ethambutol
drug DRUGBANK Spinosad
disease MESH Infectious Diseases
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH emergency
drug DRUGBANK Stavudine
disease IDO country
disease IDO contact tracing
disease MESH lymphadenopathy
disease MESH pulmonary disease
disease MESH weight gain
disease MESH meningitis
disease IDO blood
disease MESH complications
disease MESH recurrence
disease MESH co infection
disease IDO immunosuppression
disease MESH drug interaction
drug DRUGBANK Fenamole
disease IDO intervention
disease MESH tics
drug DRUGBANK Indoleacetic acid
disease MESH Treatment failure
drug DRUGBANK Trestolone
disease MESH death
disease IDO infection prevalence
disease IDO process
drug DRUGBANK Methionine
drug DRUGBANK Hexocyclium
disease MESH Extrapulmonary Tuberculosis
disease MESH adenitis
disease MESH TB meningitis
disease MESH Leprosy
disease MESH educational attainment
drug DRUGBANK Albendazole
disease IDO assay
drug DRUGBANK Ethanol
drug DRUGBANK Dihydrostreptomycin
disease MESH opportunistic infection
drug DRUGBANK Streptomycin
drug DRUGBANK Nitazoxanide
disease MESH HIV coinfection
disease MESH ramp
disease MESH causality
disease MESH Allergy
disease IDO facility
disease MESH paragonimiasis
disease MESH Buruli Ulcer
disease MESH Malnutrition
pathway REACTOME Immune System

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *